Considerations for Treatment Approaches in Intermediate-Stage HCC
Panelists discuss how emerging evidence suggests that combining transarterial chemoembolization (TACE) with systemic therapy could redefine the standard of care for hepatocellular carcinoma (HCC). Trial outcomes may drive shifts toward more personalized locoregional approaches. However, challenges in implementation include optimizing patient selection, managing toxicity, and ensuring multidisciplinary coordination.
Video content above is prompted by the following:
- Considering recent evidence, how do you envision the combination of TACE and systemic therapy evolving as a potential new standard of care?
- What potential shifts could occur in locoregional treatment approaches based on trial outcomes?
- What challenges might arise in implementing these combination strategies in routine patient care?
Gholam Contrasts Lenvatinib With Other Options in Child-Pugh B HCC
December 21st 2024During a Case-Based Roundtable® event, Pierre Gholam, MD, discussed how post hoc and real-world analyses build upon the limited available trial data for treating patients with unresectable hepatocellular carcinoma with Child-Pugh B status.
Read More
